Hanlim Pharm
Korea - SeoulBiotechnology
Focus: Hanlim Pharm is a Seoul-based biotech company founded in 2011 specializing in small molecule and generic pharmaceuticals across ophthalmology, respiratory, cardiovascular, metabolic, and immunology indications. The company operates at mid-cap biotech scale with an active clinical pipeline but limited public financial visibility.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Hanlim Pharm
AI assessmentNot HiringNo open roles listed right now. Follow Hanlim Pharm to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
13 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Bronpass Tab.
Stable
Post-LOE
Phase 4 program indicates marketed product; likely positioned as respiratory franchise anchor.
BRIDIN-plus Eye drops
Help build intelligence for Hanlim Pharm
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.